Akari Therapeutics PLC (NASDAQ:AKTX) Short Interest Up 66.7% in October

Akari Therapeutics PLC (NASDAQ:AKTX) was the recipient of a significant growth in short interest in the month of October. As of October 15th, there was short interest totaling 248,000 shares, a growth of 66.7% from the September 30th total of 148,800 shares. Based on an average trading volume of 200,400 shares, the short-interest ratio is presently 1.2 days. Currently, 0.8% of the shares of the company are sold short. Currently, 0.8% of the shares of the company are sold short. Based on an average trading volume of 200,400 shares, the short-interest ratio is presently 1.2 days.

Akari Therapeutics Stock Up 2.7%

Shares of AKTX stock opened at $0.75 on Friday. The stock’s fifty day simple moving average is $0.85 and its 200 day simple moving average is $1.07. Akari Therapeutics has a one year low of $0.57 and a one year high of $3.15.

Analyst Ratings Changes

AKTX has been the topic of several recent research reports. Maxim Group assumed coverage on Akari Therapeutics in a report on Friday, July 18th. They set a “buy” rating and a $5.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and set a $1.60 price target on shares of Akari Therapeutics in a research note on Tuesday, September 9th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Akari Therapeutics in a report on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $3.30.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.